WaferGen Biosystems said this week that it has appointed Ivan Trifunovich as president, CEO, and director.
Trifunovich is currently executive chairman, president, and CEO of Helicos Biosciences, and will continue in that role part-time. Previously, he served as senior vice president of Third Wave Technologies, now part of Hologic. Before that he held several sales and marketing and R&D positions with large pharmaceutical companies. Trifunovich received a PhD in organic chemistry from the University of California, Los Angeles, and an MBA from the University of Pennsylvania's Wharton School of Business.
Mona Chadha, WaferGen's COO and executive vice president of marketing and business development; and Donald Huffman, WaferGen's CFO, had been performing the duties of principal executive since October, when former CEO Alnoor Shivji resigned (PCR Insider, 10/20/2011).
In connection with Trifunovich's appointment, Chadha and Huffman will revert to their previous roles with the company.
Gen-Probe this week announced three changes to its management team to support "future growth" at the company.
Gen-Probe has promoted Brian Hansen to senior vice president, global sales and service; and appointed Michael Watts as vice president of Gen-Probe's Lifecodes and Prodesse units. In addition, the company has hired Albert Kildani as senior director of investor relations and corporate communications.
Hansen has been with Gen-Probe for more than six years and has led the the company's sales and service organization in the US in a number of roles during that time. In his new position, he will oversee the continued geographic expansion of Gen-Probe's commercial organization throughout the world.
Watts has managed Gen-Probe's investor relations and corporate communications efforts for more than eight years. In his new role, he will lead the company's efforts to profitably grow its recently acquired business units focusing on transplant diagnostics and infectious disease testing.
Kildani joins Gen-Probe after a 14-year career on Wall Street as a sell-side research analyst, investment banker, and buy-side analyst in the healthcare space with a focus on the molecular diagnostics industry.
Thermo Fisher Scientific this week elected Martin Harris to its board of directors. Harris has also been appointed to the board’s nominating and governance committee.
Harris currently serves as chief information officer and chairman of the information technology division of Cleveland Clinic in Ohio. He is also responsible for strategic business planning for Cleveland Clinic. Harris also currently serves as a member of the board of Invacare Corporation and HealthStream.